209 related articles for article (PubMed ID: 38237681)
1. Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by
Sharma AK; Pei J; Yang Y; Dyba M; Smith B; Rabara D; Larsen EK; Lightstone FC; Esposito D; Stephen AG; Wang B; Beltran PJ; Wallace E; Nissley DV; McCormick F; Maciag AE
J Biol Chem; 2024 Feb; 300(2):105650. PubMed ID: 38237681
[TBL] [Abstract][Full Text] [Related]
2. NMR
Sharma AK; Dyba M; Tonelli M; Smith B; Gillette WK; Esposito D; Nissley DV; McCormick F; Maciag AE
Biomol NMR Assign; 2022 Apr; 16(1):1-8. PubMed ID: 34686998
[TBL] [Abstract][Full Text] [Related]
3. GTP Binding and Oncogenic Mutations May Attenuate Hypervariable Region (HVR)-Catalytic Domain Interactions in Small GTPase K-Ras4B, Exposing the Effector Binding Site.
Lu S; Banerjee A; Jang H; Zhang J; Gaponenko V; Nussinov R
J Biol Chem; 2015 Nov; 290(48):28887-900. PubMed ID: 26453300
[TBL] [Abstract][Full Text] [Related]
4. Reduced dynamic complexity allows structure elucidation of an excited state of KRAS
Chao FA; Chan AH; Dharmaiah S; Schwieters CD; Tran TH; Taylor T; Ramakrishnan N; Esposito D; Nissley DV; McCormick F; Simanshu DK; Cornilescu G
Commun Biol; 2023 Jun; 6(1):594. PubMed ID: 37268708
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic mutations Q61L and Q61H confer active form-like structural features to the inactive state (state 1) conformation of H-Ras protein.
Matsumoto S; Taniguchi-Tamura H; Araki M; Kawamura T; Miyamoto R; Tsuda C; Shima F; Kumasaka T; Okuno Y; Kataoka T
Biochem Biophys Res Commun; 2021 Aug; 565():85-90. PubMed ID: 34102474
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for conformational dynamics of GTP-bound Ras protein.
Shima F; Ijiri Y; Muraoka S; Liao J; Ye M; Araki M; Matsumoto K; Yamamoto N; Sugimoto T; Yoshikawa Y; Kumasaka T; Yamamoto M; Tamura A; Kataoka T
J Biol Chem; 2010 Jul; 285(29):22696-705. PubMed ID: 20479006
[TBL] [Abstract][Full Text] [Related]
7. NMR
Sharma AK; Lee SJ; Zhou M; Rigby AC; Townson SA
Biomol NMR Assign; 2019 Apr; 13(1):227-231. PubMed ID: 30798456
[TBL] [Abstract][Full Text] [Related]
8. Real-time monitoring of the reaction of KRAS G12C mutant specific covalent inhibitor by in vitro and in-cell NMR spectroscopy.
Zhao Q; Haga R; Tamura S; Shimada I; Nishida N
Sci Rep; 2023 Nov; 13(1):19253. PubMed ID: 37935773
[TBL] [Abstract][Full Text] [Related]
9. Conformational Dynamics Allows Sampling of an "Active-like" State by Oncogenic K-Ras-GDP.
Grudzien P; Jang H; Leschinsky N; Nussinov R; Gaponenko V
J Mol Biol; 2022 Sep; 434(17):167695. PubMed ID: 35752212
[TBL] [Abstract][Full Text] [Related]
10. Conformational states of Ras complexed with the GTP analogue GppNHp or GppCH2p: implications for the interaction with effector proteins.
Spoerner M; Nuehs A; Ganser P; Herrmann C; Wittinghofer A; Kalbitzer HR
Biochemistry; 2005 Feb; 44(6):2225-36. PubMed ID: 15697248
[TBL] [Abstract][Full Text] [Related]
11. NMR
Yuan C; Hansen AL; Bruschweiler-Li L; Brüschweiler R
Biomol NMR Assign; 2024 Jun; 18(1):7-13. PubMed ID: 37948018
[TBL] [Abstract][Full Text] [Related]
12. The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B.
Lu S; Jang H; Nussinov R; Zhang J
Sci Rep; 2016 Feb; 6():21949. PubMed ID: 26902995
[TBL] [Abstract][Full Text] [Related]
13.
Pálfy G; Vida I; Perczel A
Biomol NMR Assign; 2020 Apr; 14(1):1-7. PubMed ID: 31468366
[TBL] [Abstract][Full Text] [Related]
14. Delineating the RAS Conformational Landscape.
Parker MI; Meyer JE; Golemis EA; Dunbrack RL
Cancer Res; 2022 Jul; 82(13):2485-2498. PubMed ID: 35536216
[TBL] [Abstract][Full Text] [Related]
15. Molecular assemblies of the catalytic domain of SOS with KRas and oncogenic mutants.
Moghadamchargari Z; Shirzadeh M; Liu C; Schrecke S; Packianathan C; Russell DH; Zhao M; Laganowsky A
Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33723061
[TBL] [Abstract][Full Text] [Related]
16. Conformational states of human rat sarcoma (Ras) protein complexed with its natural ligand GTP and their role for effector interaction and GTP hydrolysis.
Spoerner M; Hozsa C; Poetzl JA; Reiss K; Ganser P; Geyer M; Kalbitzer HR
J Biol Chem; 2010 Dec; 285(51):39768-78. PubMed ID: 20937837
[TBL] [Abstract][Full Text] [Related]
17. A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation.
Yin G; Kistler S; George SD; Kuhlmann N; Garvey L; Huynh M; Bagni RK; Lammers M; Der CJ; Campbell SL
J Biol Chem; 2017 Mar; 292(11):4446-4456. PubMed ID: 28154176
[TBL] [Abstract][Full Text] [Related]
18. The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS.
Li C; Vides A; Kim D; Xue JY; Zhao Y; Lito P
Science; 2021 Oct; 374(6564):197-201. PubMed ID: 34618566
[TBL] [Abstract][Full Text] [Related]
19. An NMR comparison of the changes produced by different guanosine 5'-triphosphate analogs in wild-type and oncogenic mutant p21ras.
Miller AF; Halkides CJ; Redfield AG
Biochemistry; 1993 Jul; 32(29):7367-76. PubMed ID: 8338834
[TBL] [Abstract][Full Text] [Related]
20. 2'-Deoxy Guanosine Nucleotides Alter the Biochemical Properties of Ras.
Yun SD; Scott E; Moghadamchargari Z; Laganowsky A
Biochemistry; 2023 Aug; 62(16):2450-2460. PubMed ID: 37487239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
